不同基础免疫程序后接种蜱传脑炎疫苗加强针的第二项五年随访显示抗体至少持续10年
这项在捷克开展的IV期开放标签单中心第二扩展研究,纳入既往接受三种基础免疫程序并接种加强针的健康成人和青少年,每年检测抗蜱传脑炎病毒中和抗体至加强后10年。结果显示所有筛查人群90-100%维持保护阈值(中和抗体滴度≥10),几何平均滴度134-343,各基础程序间无差异,年龄较大组滴度较低但10年时仍高于阈值。
要点
- 加强后6至10年,所有筛查人群中90-100%维持中和抗体滴度≥10的保护阈值。
- 几何平均滴度在全筛查集中为134-343,各基础免疫程序间无差异。
- 年龄较大组几何平均滴度总体较低,但10年时仍高于中和抗体滴度≥10。
核心结论
- 本研究显示,无论基础免疫程序如何,所有年龄组在接种TBEvac第一剂加强针后长达10年仍存在抗TBEV中和抗体。
研究设计与样本
- IV期、开放标签、单中心、第二扩展研究(NCT01562444),在捷克开展。
- 纳入在母研究中接受3种不同基础免疫程序(快速、常规和加速常规)并在第一扩展研究前(基础系列完成后12-18个月)或开始时(基础系列完成后3年)接种加强针的健康成人和青少年(≥12岁)。
- 每年采集血样,通过中和试验(NT)抗体检测评估抗TBEV抗体反应,分析在全人群和按年龄分层(15-49岁、≥50岁、≥60岁)进行。
- 筛查206人,191人完成研究。
主要发现
- 在所有时间点,全筛查集中90-100%的参与者和符合方案集中≥97%的参与者达到临床意义保护阈值(NT滴度≥10),无论基础免疫程序如何。
- 全筛查集中抗体几何平均滴度(GMTs)为134至343。
- 年龄较大组总体GMTs较低,但所有组GMTs至第10年仍高于NT滴度≥10。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tick borne encephalitis (TBE) endemic zones are expanding. We previously evaluated long term persistence of antibody 5 years after the first booster immunization following different primary immunization schedules with the polygeline-free inactivated TBE vaccine (TBEvac) in adults and adolescents. Here, we report anti-TBE virus (TBEV) antibody persistence from 6 to 10 years post-booster administration. METHODS: This was a phase IV, open-label, single-center, second extension study (NCT01562444), conducted in Czechia. Healthy adults and adolescents ≥12 years who had received 3 different primary vaccination schedules (rapid, conventional and accelerated conventional) in the parent study and a booster dose before (12-18 months post-primary series completion) or at the beginning (3 years post-primary series completion) of the first extension study were screened and enrolled in this study. Blood samples were collected yearly and anti-TBEV antibody response was evaluated by neutralizing test (NT) antibody assays. Analysis was performed overall and per age strata: 15-49 years, ≥50 years, and ≥60 years. RESULTS: Of 206 screened individuals, 191 completed the study. Overall, 90-100% of participants in the all-screened set and ≥97% in the per-protocol set had the clinically meaningful threshold of protection (NT titers ≥10) across all timepoints, regardless of the primary vaccination schedule. Overall, antibody geometric mean titers (GMTs) varied from 134 to 343 in the all-screened set. Older age groups showed overall lower GMTs, although GMTs remained higher than NT titers ≥10 up to year 10 in all groups. CONCLUSION: This study showed long-term persistence of anti-TBEV NT antibodies for up to 10 years after the first booster dose of TBEvac in all age groups, regardless of the primary vaccination schedule.
引用
- Beran J, Lattanzi M, Xie F, et al. Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence. Vaccine. 2018. PMID: 29397225. doi:10.1016/j.vaccine.2017.12.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。